Gyre Therapeutics, Inc. GYRE Gyre Pharmaceuticals — Segment Expenditure Addition To Long Lived Assets

Other segment segments

Similar metrics at other companies

EXPCement — Segment Expenditure Addition To Long Lived Assets

$66.86M+45.4%

NUSHong Kong Taiwan — Segment Expenditure Addition To Long Lived Assets

$15K-71.2%

FSISegment Expenditure Addition To Long Lived Assets

$2.23M+531%

RDI

RDIAll Segments — Segment Expenditure Addition To Long Lived Assets

$556K+36.9%

MLMReportable Segments — Segment Expenditure Addition To Long Lived Assets

$2.51B+1,801%

CCAll Segments — Segment Expenditure Addition To Long Lived Assets

$43M+2.4%

FAQ

What is Gyre Therapeutics, Inc.'s gyre pharmaceuticals — segment expenditure addition to long lived assets?

Gyre Therapeutics, Inc. (GYRE) reported gyre pharmaceuticals — segment expenditure addition to long lived assets of $208K in Q2 2026.

How has Gyre Therapeutics, Inc.'s gyre pharmaceuticals — segment expenditure addition to long lived assets changed year-over-year?

Gyre Therapeutics, Inc.'s gyre pharmaceuticals — segment expenditure addition to long lived assets decreased by 18.8% year-over-year, from $256K to $208K.

What is the long-term trend for Gyre Therapeutics, Inc.'s gyre pharmaceuticals — segment expenditure addition to long lived assets?

Over 2 years (2023 to 2025), Gyre Therapeutics, Inc.'s gyre pharmaceuticals — segment expenditure addition to long lived assets has grown at a -62.6% compound annual growth rate (CAGR), from $8.52M to $1.19M.

What does gyre pharmaceuticals — segment expenditure addition to long lived assets mean?

This measures the capital investment made by the segment to acquire or improve long-term assets such as property, plant, and equipment. It reflects the segment's commitment to infrastructure growth and capacity expansion. High levels of expenditure indicate ongoing investment in the segment's future operational capabilities.